Piperazine edetate calcium
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Piperazine edetate calcium
- Molecular weight
- 416.44
- Structure (SMILES)
- C1CNCCN1.O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)O)CC(=O)O.[Ca+2]
- calciate 2 n n 1 2 ethanediylbis n carboxymethyl glycinato 4 n n o o on on oc 6 21 dihydrogen compd with piperazine 1 1
- CALCIATE(2-), ((N,N'-1,2-ETHANEDIYLBIS(N-(CARBOXYMETHYL)GLYCINATO))(4-)-N,N',O,O',ON,ON')-, (OC-6-21)-, DIHYDROGEN, COMPD. WITH PIPERAZINE (1:1)
- edetato de piperazina y calcio
- Edetato de piperazina y calcio
- justelmin
- Justelmin
- monocalcium monopiperaziniumethylenediamine tetraacetate
- MONOCALCIUM MONOPIPERAZINIUMETHYLENEDIAMINE TETRAACETATE
- perin
- Perin
- piperazine adipate
- Piperazine adipate
- piperazine calcium edathamil
- Piperazine calcium edathamil
- piperazine calcium edetate
- Piperazine calcium edetate
- piperazine calcium edetate [INN]
- piperazine calcium edetate inn
- piperazine edetate calcium
- Piperazine edetate calcium
- PIPERAZINE EDETATE CALCIUM [MI]
- PIPERAZINE EDETATE CALCIUM [USAN]
- piperazine edetate calcium mi
- piperazine edetate calcium usan
- piperazine edetate de calcium
And 1 more, listed on the interactive page.
- CAS registry numbers
- 12002-30-1
- ChEMBL ID
- CHEMBL2106963
- InChIKey
- ROJMAHHOFDIQTI-UHFFFAOYSA-L
- FDA ingredient codes (UNII)
- L4QEN8344Z
- 31213
- 23724991
- 76955902
- 140382232
- First in class
- No
- Orphan designation
- No
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Heavy atoms
- 27
- Molecular formula
- C14H24CaN4O8
- Monoisotopic mass
- 416.1220046
- Natural product
- No
Related records
Trials (122)
- "Quick-starting" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition
- 2013/2017 H7N9 Prime-Boost Interval
- A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg
- A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
- A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
- A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.
- A Phase 3 Study in Participants With Moderate to Severe Psoriasis
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
- A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test
- A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test
- A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine
- A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
- A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
- A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
- A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
- A Study of Idazoxan in Healthy Participants
- A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC